留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

哌拉西林钠-他唑巴坦钠优选给药方案的评估及应用的研究现状

李园园,  于锋

downloadPDF
文章导航 > 药学实践与服务  > 2014 >  32(6): 416-418,452
李园园, 于锋. 哌拉西林钠-他唑巴坦钠优选给药方案的评估及应用的研究现状[J]. 药学实践与服务, 2014, 32(6): 416-418,452. doi: 10.3969/j.issn.1006-0111.2014.06.005
引用本文: 李园园, 于锋. 哌拉西林钠-他唑巴坦钠优选给药方案的评估及应用的研究现状[J]. 药学实践与服务, 2014, 32(6): 416-418,452. doi: 10.3969/j.issn.1006-0111.2014.06.005
shu
LI Yuanyuan, YU Feng. Current situation of evaluation and application with alternative dosing regimens for piperacillin sodium-tazobactam sodium[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 416-418,452. doi: 10.3969/j.issn.1006-0111.2014.06.005
Citation: LI Yuanyuan, YU Feng. Current situation of evaluation and application with alternative dosing regimens for piperacillin sodium-tazobactam sodium[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 416-418,452. doi: 10.3969/j.issn.1006-0111.2014.06.005
shu

哌拉西林钠-他唑巴坦钠优选给药方案的评估及应用的研究现状

doi: 10.3969/j.issn.1006-0111.2014.06.005

  • 中国药科大学临床药学教研室, 江苏 南京 210009

Current situation of evaluation and application with alternative dosing regimens for piperacillin sodium-tazobactam sodium

  • Depamt, emt pf Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, China

  • 摘要: 目的 为哌拉西林钠-他唑巴坦钠的临床合理用药提供参考。 方法 对哌拉西林钠-他唑巴坦钠的优选给药方案的药动/药效学研究、临床试验及具体实施情况进行综述。 结果 哌拉西林钠-他唑巴坦钠的优选给药方案(延长输注或持续输注)可最大化地达到药效学目标,改善临床有效性。 结论 需积极完善优化方案用于临床实践的策略。
    Abstract: Objective To offer reference to reasonable clinical use of piperacillin sodium sodium-tazobactam sodium. Methods We reviewed pharmacokinetic/ pharmacodynamic studies, clinical trails and implementation of piperacillin sodium-tazobactam sodium alternative dosing regimen in recent. Results The alternative dosing regimens, prolonged and continuous infusion, could maximise the likelihood of achieving desirable pharmacodynamic targets and improve clinical effectiveness. Conclusion It's needed to improve the strategies of alternative dosing regimens for clinical practice.
  • [1] Gin A, Dilay L, Karlowsky JA, et al. Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination[J].Expert Rev Antiinfect Ther, 2007, 5(3): 365-383.
    [2] Niederman MS, Craven D, Bonten M, et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia[J].Am J Respir Crit Care Med, 2005, 171(4): 388-416.
    [3] Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the society of infectious diseases pharmacists[J].Pharmacotherapy, 2006, 26(9): 1320-1332.
    [4] Kim A, Sutherland CA, Kuti JL, et al. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?[J].Pharmacotherapy, 2007, 27(11): 1490-1497.
    [5] Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore[J].Clin Infect Dis, 2007, 44(1): 79-86.
    [6] 叶龙强, 蔡 挺. 蒙特卡罗药动药效学模型在优化抗菌药物给药方案中的应用[J].现代实用医学, 2009, 21(1): 5-6,36.
    [7] DeRyke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from the United States intensive care units in 2004[J].Pharmacotherapy, 2007, 27(3): 333-342.
    [8] Rotschafer JC, Ullman M. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulation and steady-state pharmacokinetic data from hospitalized patients[J].Ann Pharmacother, 2009, 43(11): 1887-1889.
    [9] Burgess DS, Waldrep T. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing[J].Clin Ther, 2002, 24(7): 1090-1104.
    [10] Roberts JA. Relevance of pharmacokinetics to antibiotic dosing in critically ill patients[J].Curr Pharm Biotechnol, 2011, 12(12): 1981-1982.
    [11] Roberts JA, Kirkpatrick CM, Roberts MS, et al. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis[J].Int J Antimicrob Agents, 2010, 35(2): 156-163.
    [12] Roberts JA, Roberts MS, Robertson TA, et al. Piperacillin penetration into tissue of critically ill patients with sepsis—bolus versus continuous administration?[J].Crit Care Med, 2009, 37(3): 926-933.
    [13] Rafati MR, Rouini MR, Mojtahedzadeh M, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients[J].Int J Antimicrob Agents, 2006, 28(2): 122-127.
    [14] Reese AM, Frei CR, Burgess DS. Pharmacodynamics of intermittent and continuous infusion piperacillin/tazobactam and cefepime against extended-spectrum beta-lactamase-producing organisms[J].Int J Antimicrob Agents, 2005, 26(2): 114-119.
    [15] 蔡 挺, 叶龙强. 3种β-内酰胺类抗菌药物延长及持续输注对产ESBLs细菌的药效学研究[J].中华医院感染学杂志, 2010, 20(14): 2110-2113.
    [16] Li C, Kuti JL, Nightingale CH, et al. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection[J].J Antimicrob Chemother, 2005, 56(2): 388-395.
    [17] Zelenitsky SA, Ariano RE, Zhanel GG. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data[J].J Antimicrob Chemother, 2011, 66(2): 343-349.
    [18] Koomanachai P, Bulik CC, Kuti JL, et al. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States[J].Clin Ther, 2010, 32(4): 766-779.
    [19] Shea KM, Cheatham SC, Wack MF, et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients[J].Int J Antimicrob Agents, 2009, 34(5): 429-433.
    [20] Cockerill F.Performance Standards for Antimicrobial susceptibility testing: twenty-second informational supplement[M]. Colorado:Clinical and Laboratory Standards Institute, 2012.
    [21] Kim A, Kuti JL, Nicolau DP. Probability of pharmacodynamic target attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia[J].Clin Ther, 2009, 31(11): 2765-2778.
    [22] Cheatham SC, Fleming MR, Healy DP, et al. Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients[J].Int J Antimicrob Agents, 2013, 41(1): 52-56.
    [23] Patel N, Scheetz MH, Drusano GL, et al. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients[J].Antimicrob Agents Chemother, 2010, 54(1): 460-465.
    [24] Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics[J].Crit Care Med, 2009, 37(6): 2071-2078.
    [25] Grant EM, Kuti JL, Nicolau DP, et al. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital[J].Pharmacotherapy, 2002, 22(4): 471-483.
    [26] Florea NR, Kotapati S, Kuti JL, et al. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study[J].Am J Health Syst Pharm, 2003, 60(22): 2321-2327.
    [27] Lodise TP, Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy[J].Clin Infect Dis, 2007, 44(3): 357-363.
    [28] Yost RJ, Cappelletty DM. The retrospective cohort of extended-infusion piperacillin-tazobactam (RECEIPT) study: a multicenter study[J]. Pharmacotherapy, 2011, 31(8): 767-775.
    [29] 叶龙强, 蔡 挺, 金雨虹, 等. 延长哌拉西林/他唑巴坦输注时间治疗革兰阴性杆菌感染的临床研究[J].中华医院感染学杂志, 2011, 21(16): 3476-3479.
    [30] 黄永婵, 庞晓军. 延长哌拉西林他唑巴坦给药时间法治疗铜绿假单胞菌感染的临床研究[J].广西医科大学学报, 2012, 29(3): 381-383.
    [31] Patel GW,Patel N, Lat A,et al.Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections[J].Diagn Microbiol Infect Dis, 2009, 64(2): 236-240.
    [32] Xamplas RC,Itokazu GS,Glowacki RC,et al.Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital[J].Am J Health Syst Pharm, 2010, 67(8): 622-628.
    [33] Heinrich LS, Tokumaru S, Clark NM, et al. Development and implementation of a piperacillin-tazobactam extended infusion guideline[J].J Pharm Pract, 2011, 24(6): 571-576.
  • [1] 桂明珠, 李静, 李志玲.  儿童伏立康唑的血药浓度与CYP2C19、CYP2C9和CYP3A5基因多态性的相关性研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202402020
    [2] 王鹏, 陈顺, 赵逸, 高守红, 王志鹏.  卡培他滨致小鼠手足综合征模型的建立及评价 . 药学实践与服务, 2024, 42(9): 385-388, 398. doi: 10.12206/j.issn.2097-2024.202308045
    [3] 丁千雪, 尚圣兰, 余梦辰, 余爱荣.  机器学习在肾病综合征患者他克莫司个体化用药中的应用 . 药学实践与服务, 2024, 42(6): 227-230, 243. doi: 10.12206/j.issn.2097-2024.202310007
    [4] 石晓萍, 吕迁洲, 李晓宇, 许青.  泊沙康唑对比伏立康唑经验治疗或诊断驱动治疗免疫功能低下患者侵袭性霉菌病的成本-效果分析 . 药学实践与服务, 2024, 42(12): 512-519. doi: 10.12206/j.issn.2097-2024.202401050
    [5] 杨凤艳, 张月, 陈恩贤, 缪雪蓉, 魏凯.  瑞马唑仑临床应用研究进展 . 药学实践与服务, 2024, 42(9): 365-374. doi: 10.12206/j.issn.2097-2024.202405026
    [6] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(8): 334-340. doi: 10.12206/j.issn.2097-2024.202303023
    [7] 陈春娟, 郑志新, 李骊.  平喘方联合孟鲁司特钠治疗儿童支气管哮喘的临床疗效观察 . 药学实践与服务, 2024, 42(12): 524-527, 532. doi: 10.12206/j.issn.2097-2024.202405035
    [8] 崔亚玲, 吴琼, 马良煜, 胡北, 姚东, 许子华.  肝素钠肌醇烟酸酯乳膏中肌醇烟酸酯皮肤药动学研究 . 药学实践与服务, 2024, 42(): 1-5. doi: 10.12206/j.issn.2097-2024.202404006
    [9] 崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺.  临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  2712
  • HTML全文浏览量:  225
  • PDF下载量:  232
  • 被引次数: 0
出版历程
  • 收稿日期:  2013-07-21
  • 修回日期:  2013-12-02

哌拉西林钠-他唑巴坦钠优选给药方案的评估及应用的研究现状

doi: 10.3969/j.issn.1006-0111.2014.06.005
  • 中国药科大学临床药学教研室, 江苏 南京 210009
  • 收稿日期: 2013-07-21
  • 修回日期: 2013-12-02

摘要: 目的 为哌拉西林钠-他唑巴坦钠的临床合理用药提供参考。 方法 对哌拉西林钠-他唑巴坦钠的优选给药方案的药动/药效学研究、临床试验及具体实施情况进行综述。 结果 哌拉西林钠-他唑巴坦钠的优选给药方案(延长输注或持续输注)可最大化地达到药效学目标,改善临床有效性。 结论 需积极完善优化方案用于临床实践的策略。

English Abstract

李园园, 于锋. 哌拉西林钠-他唑巴坦钠优选给药方案的评估及应用的研究现状[J]. 药学实践与服务, 2014, 32(6): 416-418,452. doi: 10.3969/j.issn.1006-0111.2014.06.005
引用本文: 李园园, 于锋. 哌拉西林钠-他唑巴坦钠优选给药方案的评估及应用的研究现状[J]. 药学实践与服务, 2014, 32(6): 416-418,452. doi: 10.3969/j.issn.1006-0111.2014.06.005
shu
LI Yuanyuan, YU Feng. Current situation of evaluation and application with alternative dosing regimens for piperacillin sodium-tazobactam sodium[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 416-418,452. doi: 10.3969/j.issn.1006-0111.2014.06.005
Citation: LI Yuanyuan, YU Feng. Current situation of evaluation and application with alternative dosing regimens for piperacillin sodium-tazobactam sodium[J]. Journal of Pharmaceutical Practice and Service, 2014, 32(6): 416-418,452. doi: 10.3969/j.issn.1006-0111.2014.06.005
shu

    全文HTML

参考文献 (33)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计